MA-NETSCOUT-SYSTEMS
25.4.2024 12:06:33 CEST | Business Wire | Press release
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) today released findings from its 2H2023 DDoS Threat Intelligence Report that dissects trends and attack methodologies adversaries use against service providers, enterprises, and end-users. The information cited in the report is gathered from NETSCOUT’s unparalleled internet visibility at a global scale, collecting, analyzing, prioritizing, and disseminating data on DDoS attacks from 214 countries and territories, 456 vertical industries, and more than 13,000 Autonomous System Numbers (ASNs). Driven by tech-savvy and politically motivated hacktivist groups and an increase in DNS water torture attacks, NETSCOUT observed more than 7 million DDoS attacks in the second half of 2023, representing a 15% increase from the first half.
Hacktivism Increases Ten-Fold
DDoS (Distributed Denial-of-Service) hacktivism transcended geographic borders during the past year, exemplifying a shift in the global security landscape. Groups like NoName057(016) and Anonymous Sudan, as well as lone hackers and small collectives, are increasingly using DDoS to target those ideologically opposed to them, for example:
- Peru experienced a 30% increase in attacks tied to protests of former Peruvian President Fujimori’s release from prison on December 6.
- Poland experienced a surge in attacks at the end of 2023 associated with a regime change and statements reaffirming Poland’s support of Ukraine in the Russia-Ukraine conflict.
- Anonymous Sudan attacked X (formerly Twitter) to influence Elon Musk regarding Starlink service in Sudan, and it attacked Telegram for suspending its main channel.
NoName057(016), Anonymous Sudan, and Killnet have taken credit for DDoS attacks in Ukraine, Russia, Israel, and Palestine targeting communications infrastructure, hospitals, and banks. Daily attacks from hacktivists increased more than ten-fold between the first and second halves of 2023. NoName057(016) topped the list of DDoS adversaries in 2023, targeting 780 websites across 35 countries.
Water Torture Attacks Rise
Targeting critical systems at the heart of the Internet's control plane, DNS (Domain Name System) water torture attacks have been on the rise since the end of 2019. DNS query floods designed to overwhelm authoritative DNS servers experienced a massive 553% increase from 1H2020 to 2H2023. Rather than targeting one website or server, adversaries go after entire systems, resulting in even more damage.
Gaming and Gambling Targeted
NETSCOUT findings point to gaming -- and the gambling associated with gaming – as a primary target for DDoS attacks. Threat actors are drawn to the sector’s substantial financial value and the goal of disrupting competitors, especially during online esports tournaments. Historically, 80-90% of all DDoS attacks are related to gaming and gambling. NETSCOUT assessed attacks on enterprises in these sectors, determining that more than 100,000 DDoS attacks were deployed against those in gaming, and over 20,500 were made against those tied to gambling in 2023.
In addition, based on NETSCOUT’s observations of the DDoS threat landscape, approximately 1% of DDoS attacks are suppressed from originating networks.
“Global adversaries have become more sophisticated in the past year attacking websites and overloading servers to lockout customers and inflict digital chaos to influence geopolitical issues,” stated Richard Hummel, senior threat intelligence lead, NETSCOUT. “The relentless barrage of DDoS threats drives up costs and creates security fatigue for network operators. They cannot safeguard their digital assets without the proper advanced DDoS protection leveraging predictive, real-time threat intelligence.”
Multiple decades of experience working with the world’s largest service providers and enterprises give NETSCOUT far-reaching visibility into the global internet to discern the pulse of the digital world. Our capacity to monitor and respond to DDoS attacks is powered by our ATLAS platform, which enables us to analyze an impressive 500 terabits per second (Tbps) of network traffic.
Visit our interactive website for more information on NETSCOUT's DDoS Threat Intelligence Report. For real-time DDoS attack stats, map, and insights, visit NETSCOUT Cyber Threat Horizon.
About NETSCOUT
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) protects the connected world from cyberattacks and performance and availability disruptions through the company’s unique visibility platform and solutions powered by its pioneering deep packet inspection at scale technology. NETSCOUT serves the world’s largest enterprises, service providers, and public sector organizations. Learn more at www.netscout.com or follow @NETSCOUT on LinkedIn, X, or Facebook.
©2024 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Visibility Without Borders, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, Omnis, and TrueCall are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240425443965/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
